Ibrutinib Could Enhance CAR T-Cell Treatment Impact in CLL – OncLive
OncLiveIbrutinib Could Enhance CAR T-Cell Treatment Impact in CLLOncLiveTreatment with concurrent ibrutinib improves expansion of chimeric antigen receptor T-cells and could subsequently improve response in patients with chronic …and more &… Continue reading
